Skip to main content
. Author manuscript; available in PMC: 2019 Apr 1.
Published in final edited form as: Med Decis Making. 2018 Apr;38(1 Suppl):9S–23S. doi: 10.1177/0272989X17700624

Figure 3.

Figure 3

Treatment dissemination. The figure depicts use of adjuvant systemic treatment dissemination from 1975–2010 for an exemplar stage and set of molecular markers (node positive stage IIb, ER+/HER2−) among women 50 to 69 years of age at diagnosis. In the 1980’s and early 1990’s multi-agent chemotherapy (blue line) included primarily CMF regimens; starting in the mid-1990’s antracycline-based regimens were included and increased in use, and in 1998 taxanes could be added to those regimens. Hormonal therapy (red line) began with tamoxifen in the 1980’s and starting in 1997 also included aromatase inhibitors. Hormonal therapy could be used alone or in combination with multi-agent chemotherapy (“both”, green line). Over time, there was an increasing use of both multi-agent chemotherapy and hormonal therapy.